http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 17 Jun 2026 19:45:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Enliven+Therapeutics%2C+++++For%3A+Jun+15++Filed+by%3A+OrbiMed+Genesis+GP+LLC/26661418.html si-local-file:///var/storage/secattach/20260617/26661418.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Enliven+Therapeutics%2C+++++For%3A+Jun+15++Filed+by%3A+OrbiMed+Genesis+GP+LLC/26661418.html Wed, 17 Jun 2026 19:45:00 -0400 ELVN O.47043299 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Enliven+Therapeutics%2C+++++For%3A+Jun+15++Filed+by%3A+OrbiMed+Genesis+GP+LLC/26661418.html si-local-file:///var/storage/secattach/20260617/26661418.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Enliven+Therapeutics%2C+++++For%3A+Jun+15++Filed+by%3A+OrbiMed+Genesis+GP+LLC/26661418.html Wed, 17 Jun 2026 19:45:00 -0400 ELVN O.47043299 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Enliven+Therapeutics%2C++++++++++++++++++Filed+by%3A+ORBIMED+ADVISORS+LLC/26661412.html si-local-file:///var/storage/secattach/20260617/26661412.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Enliven+Therapeutics%2C++++++++++++++++++Filed+by%3A+ORBIMED+ADVISORS+LLC/26661412.html Wed, 17 Jun 2026 19:42:00 -0400 ELVN O.47043299 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Enliven+Therapeutics%2C++++++++++++++++++Filed+by%3A+ORBIMED+ADVISORS+LLC/26661412.html si-local-file:///var/storage/secattach/20260617/26661412.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Enliven+Therapeutics%2C++++++++++++++++++Filed+by%3A+ORBIMED+ADVISORS+LLC/26661412.html Wed, 17 Jun 2026 19:42:00 -0400 ELVN O.47043299 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Enliven+Therapeutics%2C++++++++++++++++++Filed+by%3A+Hohl+Benjamin/26660260.html si-local-file:///var/storage/secattach/20260617/26660260.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Enliven+Therapeutics%2C++++++++++++++++++Filed+by%3A+Hohl+Benjamin/26660260.html Wed, 17 Jun 2026 16:25:00 -0400 ELVN O.47043299 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Enliven+Therapeutics%2C++++++++++++++++++Filed+by%3A+Hohl+Benjamin/26660260.html si-local-file:///var/storage/secattach/20260617/26660260.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Enliven+Therapeutics%2C++++++++++++++++++Filed+by%3A+Hohl+Benjamin/26660260.html Wed, 17 Jun 2026 16:25:00 -0400 ELVN O.47043299 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Enliven+Therapeutics%2C++++++++++++++++++Filed+by%3A+ORBIMED+CAPITAL+LLC/26649241.html si-local-file:///var/storage/secattach/20260615/26649241.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Enliven+Therapeutics%2C++++++++++++++++++Filed+by%3A+ORBIMED+CAPITAL+LLC/26649241.html Mon, 15 Jun 2026 21:24:00 -0400 ELVN O.47043299 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Enliven+Therapeutics%2C++++++++++++++++++Filed+by%3A+ORBIMED+CAPITAL+LLC/26649241.html si-local-file:///var/storage/secattach/20260615/26649241.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Enliven+Therapeutics%2C++++++++++++++++++Filed+by%3A+ORBIMED+CAPITAL+LLC/26649241.html Mon, 15 Jun 2026 21:24:00 -0400 ELVN O.47043299 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Enliven+Therapeutics%2C++++++++++++++++++Filed+by%3A+ORBIMED+ADVISORS+LLC/26649238.html si-local-file:///var/storage/secattach/20260615/26649238.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Enliven+Therapeutics%2C++++++++++++++++++Filed+by%3A+ORBIMED+ADVISORS+LLC/26649238.html Mon, 15 Jun 2026 21:21:00 -0400 ELVN O.47043299 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Enliven+Therapeutics%2C++++++++++++++++++Filed+by%3A+ORBIMED+ADVISORS+LLC/26649238.html si-local-file:///var/storage/secattach/20260615/26649238.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Enliven+Therapeutics%2C++++++++++++++++++Filed+by%3A+ORBIMED+ADVISORS+LLC/26649238.html Mon, 15 Jun 2026 21:21:00 -0400 ELVN O.47043299 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Enliven+Therapeutics%2C++++++++++++++++++Filed+by%3A+ORBIMED+ADVISORS+LLC/26649231.html si-local-file:///var/storage/secattach/20260615/26649231.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Enliven+Therapeutics%2C++++++++++++++++++Filed+by%3A+ORBIMED+ADVISORS+LLC/26649231.html Mon, 15 Jun 2026 21:19:00 -0400 ELVN O.47043299 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Enliven+Therapeutics%2C++++++++++++++++++Filed+by%3A+ORBIMED+ADVISORS+LLC/26649231.html si-local-file:///var/storage/secattach/20260615/26649231.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Enliven+Therapeutics%2C++++++++++++++++++Filed+by%3A+ORBIMED+ADVISORS+LLC/26649231.html Mon, 15 Jun 2026 21:19:00 -0400 ELVN O.47043299 http://www.streetinsider.com/Equity+Offerings/ENLIVEN+Therapeutics+closes+%24460M+public+stock+offering/26648027.html <p>Enliven Therapeutics, Inc. (NASDAQ: ELVN) closed an upsized underwritten public offering on June 15, 2026, raising approximately $460.0 million in gross proceeds before deducting underwriting discounts, commissions, and other offering expenses.</p> <p>The offering comprised 10,533,334 shares of common stock priced at $37.50 per share, including 1,600,000 additional shares from the full exercise of the underwriters' option. The company also issued pre-funded warrants to purchase 1,733,333 shares at $37.499 per warrant, representing the per-share public offering price less a $0.001 exercise price. All shares and pre-funded warrants were sold by Enliven.</p> <p>Jefferies, Goldman Sachs & Co. LLC, Morgan Stanley, and Barclays acted as http://www.streetinsider.com/Equity+Offerings/ENLIVEN+Therapeutics+closes+%24460M+public+stock+offering/26648027.html Mon, 15 Jun 2026 16:40:12 -0400 A.03080680 A.10371245 A.15776824 A.37967807 ELVN O.47043299 O.51342512 O.51342612 O.51342686 O.76935879 http://www.streetinsider.com/Equity+Offerings/ENLIVEN+Therapeutics+closes+%24460M+public+stock+offering/26648027.html <p>Enliven Therapeutics, Inc. (NASDAQ: ELVN) closed an upsized underwritten public offering on June 15, 2026, raising approximately $460.0 million in gross proceeds before deducting underwriting discounts, commissions, and other offering expenses.</p> <p>The offering comprised 10,533,334 shares of common stock priced at $37.50 per share, including 1,600,000 additional shares from the full exercise of the underwriters' option. The company also issued pre-funded warrants to purchase 1,733,333 shares at $37.499 per warrant, representing the per-share public offering price less a $0.001 exercise price. All shares and pre-funded warrants were sold by Enliven.</p> <p>Jefferies, Goldman Sachs & Co. LLC, Morgan Stanley, and Barclays acted as http://www.streetinsider.com/Equity+Offerings/ENLIVEN+Therapeutics+closes+%24460M+public+stock+offering/26648027.html Mon, 15 Jun 2026 16:40:12 -0400 A.03080680 A.10371245 A.15776824 A.37967807 ELVN O.47043299 O.51342512 O.51342612 O.51342686 O.76935879 http://www.streetinsider.com/Equity+Offerings/ENLIVEN+Therapeutics+closes+%24460M+public+stock+offering/26648027.html <p>Enliven Therapeutics, Inc. (NASDAQ: ELVN) closed an upsized underwritten public offering on June 15, 2026, raising approximately $460.0 million in gross proceeds before deducting underwriting discounts, commissions, and other offering expenses.</p> <p>The offering comprised 10,533,334 shares of common stock priced at $37.50 per share, including 1,600,000 additional shares from the full exercise of the underwriters' option. The company also issued pre-funded warrants to purchase 1,733,333 shares at $37.499 per warrant, representing the per-share public offering price less a $0.001 exercise price. All shares and pre-funded warrants were sold by Enliven.</p> <p>Jefferies, Goldman Sachs & Co. LLC, Morgan Stanley, and Barclays acted as http://www.streetinsider.com/Equity+Offerings/ENLIVEN+Therapeutics+closes+%24460M+public+stock+offering/26648027.html Mon, 15 Jun 2026 16:40:12 -0400 A.03080680 A.10371245 A.15776824 A.37967807 ELVN O.47043299 O.51342512 O.51342612 O.51342686 O.76935879 http://www.streetinsider.com/Equity+Offerings/ENLIVEN+Therapeutics+closes+%24460M+public+stock+offering/26648027.html <p>Enliven Therapeutics, Inc. (NASDAQ: ELVN) closed an upsized underwritten public offering on June 15, 2026, raising approximately $460.0 million in gross proceeds before deducting underwriting discounts, commissions, and other offering expenses.</p> <p>The offering comprised 10,533,334 shares of common stock priced at $37.50 per share, including 1,600,000 additional shares from the full exercise of the underwriters' option. The company also issued pre-funded warrants to purchase 1,733,333 shares at $37.499 per warrant, representing the per-share public offering price less a $0.001 exercise price. All shares and pre-funded warrants were sold by Enliven.</p> <p>Jefferies, Goldman Sachs & Co. LLC, Morgan Stanley, and Barclays acted as http://www.streetinsider.com/Equity+Offerings/ENLIVEN+Therapeutics+closes+%24460M+public+stock+offering/26648027.html Mon, 15 Jun 2026 16:40:12 -0400 A.03080680 A.10371245 A.15776824 A.37967807 ELVN O.47043299 O.51342512 O.51342612 O.51342686 O.76935879 http://www.streetinsider.com/Equity+Offerings/ENLIVEN+Therapeutics+closes+%24460M+public+stock+offering/26648027.html <p>Enliven Therapeutics, Inc. (NASDAQ: ELVN) closed an upsized underwritten public offering on June 15, 2026, raising approximately $460.0 million in gross proceeds before deducting underwriting discounts, commissions, and other offering expenses.</p> <p>The offering comprised 10,533,334 shares of common stock priced at $37.50 per share, including 1,600,000 additional shares from the full exercise of the underwriters' option. The company also issued pre-funded warrants to purchase 1,733,333 shares at $37.499 per warrant, representing the per-share public offering price less a $0.001 exercise price. All shares and pre-funded warrants were sold by Enliven.</p> <p>Jefferies, Goldman Sachs & Co. LLC, Morgan Stanley, and Barclays acted as http://www.streetinsider.com/Equity+Offerings/ENLIVEN+Therapeutics+closes+%24460M+public+stock+offering/26648027.html Mon, 15 Jun 2026 16:40:12 -0400 A.03080680 A.10371245 A.15776824 A.37967807 ELVN O.47043299 O.51342512 O.51342612 O.51342686 O.76935879 http://www.streetinsider.com/Equity+Offerings/ENLIVEN+Therapeutics+closes+%24460M+public+stock+offering/26648027.html <p>Enliven Therapeutics, Inc. (NASDAQ: ELVN) closed an upsized underwritten public offering on June 15, 2026, raising approximately $460.0 million in gross proceeds before deducting underwriting discounts, commissions, and other offering expenses.</p> <p>The offering comprised 10,533,334 shares of common stock priced at $37.50 per share, including 1,600,000 additional shares from the full exercise of the underwriters' option. The company also issued pre-funded warrants to purchase 1,733,333 shares at $37.499 per warrant, representing the per-share public offering price less a $0.001 exercise price. All shares and pre-funded warrants were sold by Enliven.</p> <p>Jefferies, Goldman Sachs & Co. LLC, Morgan Stanley, and Barclays acted as http://www.streetinsider.com/Equity+Offerings/ENLIVEN+Therapeutics+closes+%24460M+public+stock+offering/26648027.html Mon, 15 Jun 2026 16:40:12 -0400 A.03080680 A.10371245 A.15776824 A.37967807 ELVN O.47043299 O.51342512 O.51342612 O.51342686 O.76935879 http://www.streetinsider.com/Equity+Offerings/ENLIVEN+Therapeutics+closes+%24460M+public+stock+offering/26648027.html <p>Enliven Therapeutics, Inc. (NASDAQ: ELVN) closed an upsized underwritten public offering on June 15, 2026, raising approximately $460.0 million in gross proceeds before deducting underwriting discounts, commissions, and other offering expenses.</p> <p>The offering comprised 10,533,334 shares of common stock priced at $37.50 per share, including 1,600,000 additional shares from the full exercise of the underwriters' option. The company also issued pre-funded warrants to purchase 1,733,333 shares at $37.499 per warrant, representing the per-share public offering price less a $0.001 exercise price. All shares and pre-funded warrants were sold by Enliven.</p> <p>Jefferies, Goldman Sachs & Co. LLC, Morgan Stanley, and Barclays acted as http://www.streetinsider.com/Equity+Offerings/ENLIVEN+Therapeutics+closes+%24460M+public+stock+offering/26648027.html Mon, 15 Jun 2026 16:40:12 -0400 A.03080680 A.10371245 A.15776824 A.37967807 ELVN O.47043299 O.51342512 O.51342612 O.51342686 O.76935879 http://www.streetinsider.com/Equity+Offerings/ENLIVEN+Therapeutics+closes+%24460M+public+stock+offering/26648027.html <p>Enliven Therapeutics, Inc. (NASDAQ: ELVN) closed an upsized underwritten public offering on June 15, 2026, raising approximately $460.0 million in gross proceeds before deducting underwriting discounts, commissions, and other offering expenses.</p> <p>The offering comprised 10,533,334 shares of common stock priced at $37.50 per share, including 1,600,000 additional shares from the full exercise of the underwriters' option. The company also issued pre-funded warrants to purchase 1,733,333 shares at $37.499 per warrant, representing the per-share public offering price less a $0.001 exercise price. All shares and pre-funded warrants were sold by Enliven.</p> <p>Jefferies, Goldman Sachs & Co. LLC, Morgan Stanley, and Barclays acted as http://www.streetinsider.com/Equity+Offerings/ENLIVEN+Therapeutics+closes+%24460M+public+stock+offering/26648027.html Mon, 15 Jun 2026 16:40:12 -0400 A.03080680 A.10371245 A.15776824 A.37967807 ELVN O.47043299 O.51342512 O.51342612 O.51342686 O.76935879 http://www.streetinsider.com/Equity+Offerings/ENLIVEN+Therapeutics+closes+%24460M+public+stock+offering/26648027.html <p>Enliven Therapeutics, Inc. (NASDAQ: ELVN) closed an upsized underwritten public offering on June 15, 2026, raising approximately $460.0 million in gross proceeds before deducting underwriting discounts, commissions, and other offering expenses.</p> <p>The offering comprised 10,533,334 shares of common stock priced at $37.50 per share, including 1,600,000 additional shares from the full exercise of the underwriters' option. The company also issued pre-funded warrants to purchase 1,733,333 shares at $37.499 per warrant, representing the per-share public offering price less a $0.001 exercise price. All shares and pre-funded warrants were sold by Enliven.</p> <p>Jefferies, Goldman Sachs & Co. LLC, Morgan Stanley, and Barclays acted as http://www.streetinsider.com/Equity+Offerings/ENLIVEN+Therapeutics+closes+%24460M+public+stock+offering/26648027.html Mon, 15 Jun 2026 16:40:12 -0400 A.03080680 A.10371245 A.15776824 A.37967807 ELVN O.47043299 O.51342512 O.51342612 O.51342686 O.76935879 http://www.streetinsider.com/Equity+Offerings/ENLIVEN+Therapeutics+closes+%24460M+public+stock+offering/26648027.html <p>Enliven Therapeutics, Inc. (NASDAQ: ELVN) closed an upsized underwritten public offering on June 15, 2026, raising approximately $460.0 million in gross proceeds before deducting underwriting discounts, commissions, and other offering expenses.</p> <p>The offering comprised 10,533,334 shares of common stock priced at $37.50 per share, including 1,600,000 additional shares from the full exercise of the underwriters' option. The company also issued pre-funded warrants to purchase 1,733,333 shares at $37.499 per warrant, representing the per-share public offering price less a $0.001 exercise price. All shares and pre-funded warrants were sold by Enliven.</p> <p>Jefferies, Goldman Sachs & Co. LLC, Morgan Stanley, and Barclays acted as http://www.streetinsider.com/Equity+Offerings/ENLIVEN+Therapeutics+closes+%24460M+public+stock+offering/26648027.html Mon, 15 Jun 2026 16:40:12 -0400 A.03080680 A.10371245 A.15776824 A.37967807 ELVN O.47043299 O.51342512 O.51342612 O.51342686 O.76935879 http://www.streetinsider.com/Press+Releases/Enliven+Therapeutics+Announces+Closing+of+Upsized+Public+Offering+of+Common+Stock+and+Pre-Funded+Warrants+and+Full+Exercise+of+the+Underwriters%27+Option+to+Purchase+Additional+Shares/26648022.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.burame" idsrc="xmltag.org" >BURLINGAME, Calif.</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has closed its upsized underwritten public offering of 10,533,334 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,600,000 additional shares of its common stock, at a price to the public of <money>$37.50</money> per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,733,333 shares of its common stock http://www.streetinsider.com/Press+Releases/Enliven+Therapeutics+Announces+Closing+of+Upsized+Public+Offering+of+Common+Stock+and+Pre-Funded+Warrants+and+Full+Exercise+of+the+Underwriters%27+Option+to+Purchase+Additional+Shares/26648022.html Mon, 15 Jun 2026 16:40:00 -0400 A.03080680 A.10371245 A.15776824 A.37967807 ELVN O.47043299 O.51342512 O.51342612 O.51342686 O.76935879 http://www.streetinsider.com/Press+Releases/Enliven+Therapeutics+Announces+Closing+of+Upsized+Public+Offering+of+Common+Stock+and+Pre-Funded+Warrants+and+Full+Exercise+of+the+Underwriters%27+Option+to+Purchase+Additional+Shares/26648022.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.burame" idsrc="xmltag.org" >BURLINGAME, Calif.</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has closed its upsized underwritten public offering of 10,533,334 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,600,000 additional shares of its common stock, at a price to the public of <money>$37.50</money> per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,733,333 shares of its common stock http://www.streetinsider.com/Press+Releases/Enliven+Therapeutics+Announces+Closing+of+Upsized+Public+Offering+of+Common+Stock+and+Pre-Funded+Warrants+and+Full+Exercise+of+the+Underwriters%27+Option+to+Purchase+Additional+Shares/26648022.html Mon, 15 Jun 2026 16:40:00 -0400 A.03080680 A.10371245 A.15776824 A.37967807 ELVN O.47043299 O.51342512 O.51342612 O.51342686 O.76935879 http://www.streetinsider.com/Press+Releases/Enliven+Therapeutics+Announces+Closing+of+Upsized+Public+Offering+of+Common+Stock+and+Pre-Funded+Warrants+and+Full+Exercise+of+the+Underwriters%27+Option+to+Purchase+Additional+Shares/26648022.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.burame" idsrc="xmltag.org" >BURLINGAME, Calif.</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has closed its upsized underwritten public offering of 10,533,334 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,600,000 additional shares of its common stock, at a price to the public of <money>$37.50</money> per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,733,333 shares of its common stock http://www.streetinsider.com/Press+Releases/Enliven+Therapeutics+Announces+Closing+of+Upsized+Public+Offering+of+Common+Stock+and+Pre-Funded+Warrants+and+Full+Exercise+of+the+Underwriters%27+Option+to+Purchase+Additional+Shares/26648022.html Mon, 15 Jun 2026 16:40:00 -0400 A.03080680 A.10371245 A.15776824 A.37967807 ELVN O.47043299 O.51342512 O.51342612 O.51342686 O.76935879